MARKET WIREYahoo Finance • 6h ago
Should Value Investors Buy Cardinal Health (CAH) Stock?Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
Why CAH Stock slipped -0.24% Today — RQD Quant Desk Flash
$250.48 -0.24% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $250.97
Cardinal Health Inc. (CAH) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (4% profit margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $58.14B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CAH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Cardinal Health Inc. (NYSE: CAH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $250.48 (-0.24% 1D, market cap $58.14B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CAH ranks #53 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CAH compare to COR and MCK in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), CAH carries a Roarable B (73/100 RQD), trailing P/E of 37.2x, gross margin of 3.7%, and ROIC of 29.7%. By comparison, COR (Cencora Inc.) holds a B- grade (70/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.07B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $114.36B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CAH?
▼
Per CAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000721371), Cardinal Health Inc. generated $222.58B in revenue (-1.9% YoY), $1.56B in net income, and $1.85B in free cash flow against $58.08B in total assets and $13.59B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $250.98 (+0.20%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAH)Realized 20D OHLCV Swing Band: ±5%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY CAH SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (23% of score)
20D Institutional Volume Accumulation (±5% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0.8% FCF Margin ($1.85B FCF) & 3.7% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit12/20 pts (-8 pt drag)
Macro rate sensitivity & RSI-14 (59.1) create a -8 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$239.72+7.4% Next Q
65
Q2 (-2Q)Grade B-$257.55-4.3% Next Q
68
Q3 (-1Q)Grade B$246.45+1.6% Next Q
70
CurrentGrade B$250.48+7.1% Hist 90D α
73
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CAH Bull Thesis Could Fail
Even with a 73/100 (B) score, CAH faces multiple-compression risk if 37.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($238.58) or 200D SMA ($222.54) invalidates the momentum regime and cuts Target Base ($267.39) toward Bear Floor ($205.39).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CAH Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CAH Stock slipped -0.24% Today — RQD Quant Desk Flash
Cardinal Health Inc. (CAH) slipped -0.24% to $250.48, trading at 88% of its 52-week range ($180.45 – $259.84). High-quality cash engine (4% profit margin, 30% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 88% of its 52-week range ($180.45 – $259.84) with RSI-14 at 59.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5% around $250.48 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 3.7% gross margin and $1.9B annual free cash flow.
Live CAH Headlines & Catalysts
MARKET WIREInvestor's Business Daily • 9h ago
IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More UpsideInvestor's Business Daily report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 12h ago
Cardinal Health (CAH) Laps the Stock Market: Here's WhyYahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 15h ago
RBC Capital Sticks to Its Buy Rating for Cardinal Health (CAH)The Globe and Mail report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 18h ago
Reasons to Retain Cardinal Health Stock in Your Portfolio for NowYahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 21h ago
Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?The Globe and Mail report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 5h ago
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
MARKET WIREYahoo • 8h ago
What Analyst Projections for Key Metrics Reveal About Cardinal (CAH) Q1 EarningsLooking beyond Wall Street's top-and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September
CATALYSTBenzinga • 3d ago
Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $286Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $265 to $286.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CAH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CAH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.11%📐 HORIZONTAL RANGE
2026-11-02O $244.8H $251.1L $244.8C $250.5VOL 1.74M
RES: $259.9SUP: $214.8SMA50: $238.6SMA200: $222.5
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CAH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
28.5%/yr Implied 5Y Growth
vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CAH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CAH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CAH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAH)
Health Care Rank #53 of 1016
⚔️ COR vs CAH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CAH vs. COR, MCK, HLF, NUS)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardinal Health Inc. (CAH) ranks #53 by composite RQD confidence (73/100, grade B) and #34 by equity capitalization ($58.14B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while MCK leads on capital efficiency and profitability with 38.6% ROIC and 3.6% gross margin. MCK currently holds the highest overall quantitative score in the immediate peer group at 85/100 (A-) compared with CAH at 73/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CAH
ACTIVE
Cardinal Health Inc. | B | 73/100 | 37.2x | 3.7% | 29.7% | -0.24% | $58.14B | Benchmark Subject |
| COR Cencora Inc. | B- | 70/100 | 40.6x | 3.6% | 26.8% | +0.09% | $63.07B | /cor-vs-cah → |
| MCK McKesson Corporation | A- | 85/100 | 24.0x | 3.6% | 38.6% | +1.40% | $114.36B | /mck-vs-cah → |
| HLF Herbalife Ltd. | C | 64/100 | 5.9x | 77.9% | 34.4% | +0.93% | $1.36B | /hlf-vs-cah → |
| NUS Nu Skin Enterprises Inc. | D+ | 53/100 | — | 69.4% | 6.7% | -0.85% | $228.3M | /nus-vs-cah → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000721371In its most recent audited fiscal period (FY2025, filed 2025-06-30), Cardinal Health Inc. (CAH) reported GAAP revenue of $222.58B (-1.9% vs. FY2024 revenue of $226.83B , and +8.6% cumulative change since FY2023) , GAAP net income of $1.56B, operating cash flow of $2.40B, and free cash flow of $1.85B (-43.1% YoY). On the balance sheet, CAH closed FY2025 with $58.08B in total assets against $13.59B in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $222.58B | $1.56B | $2.40B | $1.85B | $58.08B | $13.59B |
| FY2024 (FY) | 2024-06-30 | $226.83B | $852.0M | $3.76B | $3.25B | $47.00B | $11.00B |
| FY2023 (FY) | 2023-06-30 | $204.98B | $330.0M | $2.84B | -$6.38B | $245.97B | $57.56B |
3. CAH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Cardinal Health Inc. (NYSE: CAH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $250.48 (-0.24% 1D, market cap $58.14B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CAH ranks #53 in composite RQD confidence.
How does CAH compare to COR and MCK in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), CAH carries a Roarable B (73/100 RQD), trailing P/E of 37.2x, gross margin of 3.7%, and ROIC of 29.7%. By comparison, COR (Cencora Inc.) holds a B- grade (70/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.07B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $114.36B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CAH?
Per CAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000721371), Cardinal Health Inc. generated $222.58B in revenue (-1.9% YoY), $1.56B in net income, and $1.85B in free cash flow against $58.08B in total assets and $13.59B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CAH trading relative to its 50-day, 200-day, and 52-week technical levels?
CAH last traded at $250.48 (-0.24% on volume of 1,945,008 shares), positioning the stock +4.99% above its 50-day simple moving average ($238.58) and +12.56% above its 200-day simple moving average ($222.54). Across its 52-week range of $180.45 to $259.84, CAH sits at the 88.2% percentile with a 14-day RSI of 59.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($237.96 to $263.00).
CAH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CAH stock moving today?
Why CAH Stock slipped -0.24% Today — RQD Quant Desk Flash. High-quality cash engine (4% profit margin, 30% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 73/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CAH — Cardinal Health Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:10:51Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CAH carries an RQD Score of 73, a letter grade of B, and the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are:
- Fundamental Cash Engine (16/20): Per the Roarable RQD rating, ROIC is 29.7% and FCF yield is 3.18%. This is the second-strongest pillar and suggests the business generates meaningful returns on capital, though the thin reported margins (see Financial Trend) mean the return profile is driven by capital efficiency rather than high per-dollar profit.
- Whale 13F Flow (17/20): Per the Roarable RQD rating, this is the highest-scoring pillar, citing institutional accumulation and options positioning. The underlying 13F and options detail is not itemized in the source data, so the score cannot be traced to specific holders.
- Insider Conviction (14/20): Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. Specific transactions are not itemized in the source data.
- Macro Regime Fit (12/20): Per the Roarable RQD rating, beta is 0.9 and the pillar reflects sector sensitivity. This is the lowest pillar, indicating the stock's fit with the prevailing macro regime is the least favorable component of the score.
- Forensic Balance Sheet (14/20): Per the Roarable RQD rating, Altman Z is 5.16, Piotroski F is 6/9, and Debt/Equity is 0.85. These readings point to a balance sheet the rating treats as sound.
Taken together, the score indicates that the stock's strengths are concentrated in capital returns, institutional interest, and balance sheet quality, while its weakest link is macro regime fit. For a prospective investor, the key tradeoff is valuation: per the Market Data section, trailing P/E is 37.2 and EV/EBITDA is 24.5, which means the price already embeds substantial expectations relative to reported earnings. The rating's positive verdict should be read alongside these valuation multiples rather than in isolation. This is an analytical framing, not personalized advice.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $222578.0M | $2275.0M | $1561.0M | N/A | $1850.0M | $2777.0M | $13591.4M |
| FY 2024 | $226827.0M | $1243.0M | $852.0M | N/A | $3251.0M | $3810.0M | $10998.5M |
| FY 2023 | $204979.0M | $752.0M | $330.0M | N/A | $-6380.1M | N/A | $57558.1M |
Per the SEC financials, net income rose from $330.0M (FY 2023) to $852.0M (FY 2024) and $1561.0M (FY 2025), while revenue moved from $204979.0M to $226827.0M and then $222578.0M. Debt fell from $57558.1M in FY 2023 to $13591.4M in FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 5.16 and the Piotroski F-Score is 6/9, consistent with the forensic balance sheet pillar. Per the Market Data, ROIC is 29.7% while net margin is 0.7%, and the Market Data section does not provide a historical margin series to confirm the trend.
Recent Catalysts & News Wire Analysis
Per the recent news feed, all six items are tagged to CAH with a YELLOW light and MARKET WIRE impact label:
- Yahoo Finance: "Should Value Investors Buy Cardinal Health (CAH) Stock?"
- Investor's Business Daily: "IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside"
- Yahoo Finance: "Cardinal Health (CAH) Laps the Stock Market: Here's Why"
- The Globe and Mail: "RBC Capital Sticks to Its Buy Rating for Cardinal Health (CAH)"
- Yahoo Finance: "Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"
- The Globe and Mail: "Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?"
Per the news wire, the headlines reference a buy point, an RBC Buy rating, and "medical distribution challenges in Q1." The news summaries are generic and do not disclose the underlying event details. Risk watch item: the single headline referencing distribution challenges is the only explicit negative signal. Per the Butterfly Supply-Chain Graph, the supply chain is "NONE" and proprietary signals are empty; no proprietary signal is available.
Open Questions
- What is the specific nature of the "medical distribution challenges" referenced in the Q1 news item, and what is their financial magnitude?
- Which institutional holders and options positions underlie the 17/20 Whale 13F Flow pillar?
- Which SEC Form 4 and Congressional PTR transactions drive the 14/20 Insider Conviction pillar?
- Why is EPS reported as N/A across all three financial periods despite trailing EPS of 6.74?
- What is the company's revenue and margin breakdown by business line, which the source data does not provide?
CAH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cardinal Health Inc. (CAH) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 6h ago
Should Value Investors Buy Cardinal Health (CAH) Stock? Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investor's Business Daily • 9h ago
IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside Investor's Business Daily report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 12h ago
Cardinal Health (CAH) Laps the Stock Market: Here's Why Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 15h ago
RBC Capital Sticks to Its Buy Rating for Cardinal Health (CAH) The Globe and Mail report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 18h ago
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 21h ago
Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1? The Globe and Mail report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo • 5h ago
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CAH Bull vs. Bear Conversation Board — What's Your Call at $250.48?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CAH 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $296.29 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CAH (B • RQD 73/100) a Buy at $251.09?
Welcome to the CAH (Cardinal Health Inc.) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Other Pharmaceuticals. Bulls point to capital efficiency (29.7% ROIC), while bears focus on valuation multiple compression (37.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $188.32 (-25.0%)
Spot @ $251.09 Pump the brakes on CAH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CAH, but look at what you are paying: 37.2x trailing P/E with 3.7% gross margins. Unless Cardinal Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $321.40 (+28.0%)
Spot @ $251.09 CAH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CAH, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $251.09 (52-wk range $180.45 - $259.84), any beat on forward guidance forces shorts and underweight funds to chase.